Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 667 of 5804
-
New drug aims to help mitochondrial disease patients walk farther
Disease control CompletedSPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous (SC) administration of elamipretide as a treatment for subjects with primary mitochondrial myopathy associated with nuclear DNA mu…
Phase: PHASE3 • Sponsor: Stealth BioTherapeutics Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New asthma drug cuts severe attacks in Hard-to-Treat patients
Disease control CompletedTo asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.
Phase: PHASE4 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New heart procedure could ease dual burden of heart failure and AF
Disease control Recruiting nowThe PACE-FIB trial is a multicentre, randomised, open-label clinical trial. Patients older than 18 years, with permanent AF, LVEF\>40%, average resting heart rate ≤ 110 beats per minute (bpm), at least one hospitalisation due to HF in the previous year and basal NT-proBNP level\>…
Phase: NA • Sponsor: Daniel Rodríguez Muñoz • Aim: Disease control
Last updated Jun 26, 2026 15:04 UTC
-
Glowing dye could help surgeons avoid cutting nerves
Diagnosis CompletedThis protocol describes prospective, open-label, blinded, randomized controlled, multicenter pivotal studies to evaluate bevonescein.
Phase: PHASE3 • Sponsor: Alume Biosciences, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 12:06 UTC
-
Engineered immune cells take aim at Hard-to-Treat ovarian cancer
Disease control Recruiting nowThe purpose of this first in human study is to evaluate the safety of treatment with autologous T cells genetically modified to express a CER (chimeric endocrine receptor) targeting the FSHR (follicle-stimulating hormone receptor) (FSHCER T cells), with or without conditioning ch…
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Immunotherapy combo shows promise against aggressive kidney cancer
Disease control OngoingThe NESCIO-trial is a multicenter, randomized, open-label, three-arm phase II trial investigating different combinations of neoadjuvant immunotherapy in patients with primary, resectable, intermediate to high-risk, clear-cell renal cell carcinoma. In this trial patients will be r…
Phase: PHASE2 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New heart valve fix could spare patients from Open-Heart surgery
Disease control Recruiting nowThe objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom trans…
Phase: NA • Sponsor: Abbott Medical Devices • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New alternating treatment schedule aims to improve outcomes for advanced cancer patients
Disease control Recruiting nowThe purpose of the research is to evaluate a new schedule of alternating cycles of induction chemoimmunotherapy (chemotherapy plus pembrolizumab) and immunotherapy (pembrolizumab) alone for the initial treatment of patients with advanced lung or head and neck cancers.
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New combo therapy aims to slow advanced prostate cancer
Disease control Recruiting nowThis is a single-arm, multicenter open label, international, phase II study of Bipolar Androgen Therapy (BAT) plus Radium-223 (RAD) in men with metastatic castration-resistant prostate cancer (mCRPC). Men with mCRPC with progressive disease (radiographically and/or biochemically)…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New hope for heart patients: less invasive valve procedure tested for moderate stenosis
Disease control OngoingObtain safety and effectiveness data to support indication expansion for the Medtronic TAVR System to include patients with moderate, AS.
Phase: NA • Sponsor: Medtronic Cardiovascular • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Rerouting nerves during amputation may stop phantom pain before it starts
Symptom relief TerminatedThe purpose of this study is to examine the effect of targeted muscle reinnervation on the outcomes of amputees at a level 1 trauma center. The investigators propose to randomize all patients requiring amputation with and without targeted muscle reinnervation. This study will hel…
Phase: NA • Sponsor: University of Arizona • Aim: Symptom relief
Last updated Jul 26, 2026 00:00 UTC
-
New CAR-T study aims to boost cancer treatment success
Disease control Recruiting nowThe aim of this Study is the evaluation of post-infusion CAR-T (Chimeric Antigen Receptor T Cell) expansion and persistence in patients with DLBCL, PMBCL and ALL undergoing CAR-T therapy; and the feasibility and efficacy of the treatment in the real life practice.
Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Blood test after liver surgery could personalize chemo for cancer patients
Disease control Recruiting nowTo determine if the detection of ctDNA after surgical resection of CLM can stratify patients into high and low-risk cohorts for early disease recurrence in order to inform post-operative adjuvant therapy.
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New combo aims to stall sarcomas in tough cases
Disease control Recruiting nowPhase II trial with three independent strata to independently assess the effects of the association of pembrolizumab and cabozantinib in advanced sarcomas.
Phase: PHASE2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
How often should women take the HIV prevention pill? a new study aims to find out
Prevention CompletedThe study seeks to define the expected blood levels of pre-exposure prophylaxis (PrEP) medications (tenofovir) for cisgender women taking directly observed oral PrEP therapy to understand the frequency of PrEP dosing associated with HIV protection in cisgender women. Cisgender wo…
Phase: PHASE2 • Sponsor: University of Washington • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
New injection could shrink nasal polyps without surgery
Disease control CompletedThis study will evaluate the efficacy and safety of depemokimab (GSK3511294) in participants with Chronic rhinosinusitis with nasal polyps (CRSwNP).
Phase: PHASE3 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New mobile therapy aims to curb suicide risk in older adults
Symptom relief Recruiting nowThe goal of this project is to test whether WellPATH-PREVENT (a novel, mobile psychosocial intervention) improves a specific aspect of emotion regulation, i.e., cognitive reappraisal ability, and reduces suicide risk in middle-aged and older adults (50-90 years old) who have been…
Phase: NA • Sponsor: Weill Medical College of Cornell University • Aim: Symptom relief
Last updated Jun 27, 2026 07:55 UTC
-
New drug shows promise in shrinking head and neck tumors before surgery
Disease control OngoingThe purpose of this clinical research study is to study safety and efficacy of orally administered APG-157 as the neoadjuvant/induction therapy in newly diagnosed, locally advanced patients with Head \& Neck Cancer of oral cavity and/or oropharynx. The study hypothesis is that n…
Phase: PHASE2 • Sponsor: Aveta Biomics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Experimental drug combo aims to shrink inoperable liver tumors
Disease control CompletedThis is a multicenter, single-arm, open-label phase II study to evaluate the efficacy and safety of PM8002 in combination with chemotherapy in the first-line treatment of subjects with inoperable HCC.
Phase: PHASE2 • Sponsor: Biotheus Inc. • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New CML drug combo strategy aims for deeper remission without lifelong side effects
Disease control OngoingThis study is a multicenter Phase 2, non-randomized, open-label single-group frontline study administering asciminib in patients with newly diagnosed Chronic Myeloid Leukemia-Chronic Phase (CML-CP). The aim of this study is to evaluate the efficacy and safety of asciminib in newl…
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC